Pancreatic Cancer Research

ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Nai‐Jung Chiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9292-0055; OpenAlex author ID A5040496272. Sources: OpenAlex.

Their work

Papers
29 (first author 7, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 5 papers · 2021: 2 papers · 2022: 10 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 5 papers

Papers 29

  1. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  2. Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2026.09.005↗
  3. Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience. Co-author DOI 10.1016/j.radonc.2025.111238↗
  4. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC. Co-author DOI 10.1158/1078-0432.ccr-25-4564↗
  5. NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-… First author DOI 10.1177/17588359261431386↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. First author DOI 10.1016/j.bj.2023.100696↗
  8. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  9. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. Co-author DOI 10.1186/s12929-024-01008-7↗
  10. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
  11. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. First author DOI 10.3390/cancers15041008↗
  12. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  13. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Co-author DOI 10.1016/j.ejca.2022.06.043↗
  14. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Co-author DOI 10.1038/s41416-021-01649-7↗
  15. Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study. Co-author DOI 10.1177/17588359221106558↗
  16. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. First author DOI 10.3389/fonc.2022.800842↗
  17. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers14133137↗
  18. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. First author PMID 35530292↗
  19. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗
  20. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  21. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  22. No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol. Co-author DOI 10.1038/s41598-021-94111-w↗
  23. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  24. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Co-author DOI 10.1016/j.ejca.2019.10.023↗
  25. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. First author DOI 10.1038/s41598-020-64421-6↗
  26. Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. First author DOI 10.1038/s41598-020-77250-4↗
  27. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. Co-author DOI 10.1186/s12929-020-00664-9↗
  28. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-cente… Co-author DOI 10.1371/journal.pone.0244487↗
  29. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Co-author DOI 10.1080/14656566.2016.1183646↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Shen Shan · 23 shared papers, 2016–2026 · strength 3.38
  2. Li‐Tzong Chen · 22 shared papers, 2016–2026 · strength 3.12
  3. Yung‐Yeh Su · 18 shared papers, 2020–2026 · strength 2.79
  4. Chung‐Pin Li · 15 shared papers, 2021–2026 · strength 2.54
  5. Li‐Yuan Bai · 13 shared papers, 2020–2026 · strength 1.94
  6. Jen‐Shi Chen · 12 shared papers, 2020–2026 · strength 1.74
  7. Tai‐Jan Chiu · 10 shared papers, 2021–2026 · strength 1.50
  8. Wen‐Chi Chou · 10 shared papers, 2021–2025 · strength 1.43
  9. Shih‐Hung Yang · 10 shared papers, 2021–2024 · strength 1.39
  10. Yen‐Yang Chen · 10 shared papers, 2021–2024 · strength 1.39
  11. Ying‐Jui Chao · 8 shared papers, 2020–2026 · strength 1.24
  12. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  13. Hui‐Jen Tsai · 7 shared papers, 2020–2026 · strength 1.00
  14. Chien‐Jui Huang · 6 shared papers, 2022–2024 · strength 0.99
  15. I‐Wei Ho · 2 shared papers, 2026 · strength 0.51
  16. Hung-Yuan Yu · 2 shared papers, 2026 · strength 0.50
  17. Keng-Li Lan · 2 shared papers, 2026 · strength 0.49
  18. I‐Chun Lai · 2 shared papers, 2026 · strength 0.49
  19. Yuan‐Hung Wu · 2 shared papers, 2026 · strength 0.49
  20. Siao Muk Cheng · 2 shared papers, 2024–2026 · strength 0.41
  21. Ya‐Chin Hou · 2 shared papers, 2022–2026 · strength 0.39
  22. Ping‐Jui Su · 2 shared papers, 2022–2023 · strength 0.29
  23. Ting‐Kai Liao · 2 shared papers, 2022–2023 · strength 0.29
  24. Fa‐Yauh Lee · 1 shared paper, 2026 · strength 0.27
  25. Kuei‐Chuan Lee · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.